Wealth Enhancement Advisory Services
CHRS icon

Wealth Enhancement Advisory Services’s Coherus Oncology CHRS Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$95.9K Buy
62,255
+8,684
+16% +$14.2K ﹤0.01% 3806
2026
Q1 		$92.7K Buy
53,571
+19,863
+59% +$35.3K ﹤0.01% 3334
2025
Q4 		$45.8K Buy
33,708
+5,322
+19% +$7.75K ﹤0.01% 3537
2025
Q3 		$48.5K Sell
28,386
-5,889
-17% -$6.55K ﹤0.01% 3435
2025
Q2 		$27.8K Buy
34,275
+1,026
+3% +$886 ﹤0.01% 3273
2025
Q1 		$26.8K Buy
33,249
+2,402
+8% +$2.76K ﹤0.01% 2898
2024
Q4 		$42.6K Buy
30,847
+15,214
+97% +$17.1K ﹤0.01% 2878
2024
Q3 		$16.3K Buy
+15,633
New +$21.4K ﹤0.01% 2684

Other funds holding CHRS

PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return